Scope and Claims Deep-Dive for U.S. Patent 8,962,680 (Crofelemer) and the U.S. Patent Landscape for HIV-Associated Diarrhea
U.S. Patent 8,962,680 claims methods of treating stool consistency and related endpoints in HIV-positive subjects by administering ~250 mg crofelemer per day (with dependent claims narrowing dose timing, duration, responder definitions, and subpopulations including fecal incontinence). The claim set is broad on (i) disease framing as HIV-associated diarrhea and (ii) clinical response measures but relatively narrow on (i) dosing quantity (250 mg/day core), and (ii) time windows and treatment characterization (e.g., response timing after day 3; responder definitions keyed to study endpoints).
What is U.S. Patent 8,962,680 and what claims does it cover for crofelemer in HIV-positive diarrhea?
What it covers (high level):
Method claims for improving stool consistency and relieving watery diarrhea in HIV-positive patients via crofelemer at about 250 mg/day. Dependent claims add duration ranges (days to months), response kinetics (day 3 onset; increasing improvement after day 3; increased response after 4 months), responder definition thresholds, and an incontinence-associated use frame.
Core independent claims (as provided):
- Claim 1: Treat stool consistency in an HIV-positive subject with about 250 mg crofelemer/day
- Claim 2: Improve stool consistency in an HIV-positive subject with about 250 mg/day
- Claim 3: Alleviate watery diarrhea in an HIV-positive subject with about 250 mg/day
- Claim 4: Decrease number of bowel movements per day in an HIV-positive subject with about 250 mg/day
Key dependent claim clusters:
- Duration and dosing windows
- Claims 5, 6: administering from ~1 month to ~6 months; or from ~3 days to 6 months
- Claims 10–13: at least 8 days; 8 days to 24 weeks; ~6 months; ~6 months or longer
- Claim 14: administering for duration of HIV infection
- Claims 15: response increases after crofelemer administered longer than 4 months
- Response kinetics
- Claim 7: improvement begins on day 3
- Claim 8: improvement increases with longer duration after day 3
- Responder definition (endpoint-driven)
- Claim 16: “treated” if one or more endpoints improve, including:
- decrease in bowel movements/day
- decrease in watery bowel movements/day
- improvement in daily abdominal score for pain or discomfort
- improvement in daily stool consistency score
- decrease in urgency days/week
- decrease in fecal incontinence days/week
- decrease in unscheduled visits for significant worsening of diarrhea
- Claims 17–20: narrower “treated if” statements keyed to specific primary symptom endpoints
- Claim 21: measured versus baseline
- Subpopulation framing
- Claim 9: subject “of Caucasian or Hispanic descent”
- Claim 22: decrease days/week of fecal incontinence associated with HIV-associated diarrhea or HAART-associated diarrhea via ~250 mg/day
- Alternative dosing schedule (bid dosing to reach same daily amount)
- Claims 23–27: administering ~125 mg twice daily to the subject (Claims 23–26 cover the stool consistency/bowel movement/watery diarrhea claims; Claim 27 specifically covers Claim 22’s incontinence endpoint framing)
Practical legal read of claim scope
- Front-door infringement risk: any clinical practice, label-consistent regimen, or off-label study using crofelemer ~250 mg/day to treat HIV-associated diarrhea/stool consistency and achieving the claimed endpoints can be within the claim boundaries, especially where responder definitions mirror trial endpoints.
- “Around 250 mg/day” elasticity: the claims use “about 250 mg”, which typically provides room around an exact 250 mg figure while still constraining design-around attempts that move dosing materially (for validity and infringement analysis).
- Endpoint breadth: Claim 16’s “treated if” list is wide, increasing probability that real-world outcomes could satisfy “one or more” endpoint improvements.
- Timing and duration as additional limitations: dependent claims introduce time windows and day-3 onset language. That matters for both (i) infringement theory (which claims a plaintiff pleads) and (ii) potential design-around by changing duration or onset claim framing.
How broad are the dosage and regimen limitations in 8,962,680?
Dose granularity
- Primary regimen: ~250 mg crofelemer/day (Claims 1–4, 5–22 depending on dependence chain)
- Alternative stated dosing: ~125 mg two times per day (Claims 23–27)
Regimen duration
- Claims specify multiple overlapping ranges:
- 1–6 months (Claim 5)
- 3 days–6 months (Claim 6)
- at least 8 days (Claim 10)
- 8 days–24 weeks (Claim 11)
- ~6 months (Claim 12)
- ~6 months or longer (Claim 13)
- duration of HIV infection (Claim 14)
Implications for product labeling and real-world prescribing
- These windows are compatible with typical chronic/semi-chronic supportive regimens in HIV populations. A regimen that is shorter than 8 days or materially outside 6 months can reduce alignment with dependent claims, but it does not necessarily remove risk from the independent claims (Claims 1–4), which in your text do not themselves contain duration limitations.
Do the responder endpoints create enforceable treatment-effect hooks under 8,962,680?
Claim 16 is outcome-defined
Claim 16 defines that a subject is “considered treated” if the subject demonstrates one or more of a list of improvements. This makes the claim closer to a clinical response method rather than a pure “administering” claim.
Endpoint coverage in Claim 16
- stool measures: stool consistency score, stool consistency-related decreases
- diarrhea measures: bowel movements/day, watery bowel movements/day, abdominal score for pain/discomfort
- patient burden measures: urgency days/week, fecal incontinence days/week
- safety/trajectory measure: fewer unscheduled visits for significant worsening of diarrhea
Dependent claims 17–20 narrow to single endpoints
- 17: improved daily stool consistency score
- 18: decreased stool consistency
- 19: decreased watery bowel movements/day
- 20: decreased bowel movements/day
What this means for risk
- The “one or more” structure increases infringement likelihood because it is enough to satisfy any endpoint listed.
- If evidence (trial data, post-marketing patient outcomes, or study endpoints) shows improvements consistent with the claim language, the claims are easier to map.
How do the response timing clauses (day 3 onset; post-day-3 increasing improvement; >4 months response increase) affect the landscape?
The independent claims do not require day-3 kinetics, but the dependent claims do.
Timing-dependent limitations
- Claim 7: improvement begins on day 3
- Claim 8: improvement increases with longer duration after day 3
- Claim 15: response increases after administration longer than 4 months
Strategic importance
- These clauses can shape pleading strategy (which dependent claims are asserted) and evidence burdens (trial design must show these time-linked dynamics).
- If a competitor argues that outcomes were delayed or not increasing as described, that may reduce alignment with dependent claims (but not necessarily eliminate risk under Claims 1–4 if those are asserted independently).
What does the “Caucasian or Hispanic descent” limitation change about claim coverage?
Claim 9 adds a demographic condition: subject considered of Caucasian or Hispanic descent.
Practical effect
- This is a narrower limitation than Claims 1–4. In an enforcement scenario, the patentee may prefer to assert claims that do not include Claim 9’s demographic restriction, depending on which claim set is strongest on pleading and evidence.
- For a generic or alternative dosing strategy, demographic framing can matter for infringement theories tied to specific trial populations.
How does the fecal incontinence sub-claim (Claim 22) broaden the protected uses?
Claim 22 is the incontinence-specific method:
- decrease days/week of fecal incontinence associated with either:
- HIV-associated diarrhea, or
- HAART-associated diarrhea
- via ~250 mg/day crofelemer
Downstream schedule alignment
- Claim 27: same incontinence decrease framework but using ~125 mg twice daily.
Practical effect
- This claim links crofelemer treatment to two related etiologic framings (HIV diarrhea and HAART-associated diarrhea), expanding the protected clinical narratives beyond strictly “HIV-positive stool consistency” language.
What design-around angles exist within the claim text provided?
Based strictly on the claim structure you provided:
- Dose deviation from “about 250 mg/day”
- Most direct at-risk element. Claims 23–27 suggest that 125 mg BID is also within scope when aligned to the claimed endpoints.
- Moving to a daily dose that is not “about 250 mg” is a plausible design-around direction, but only a court-level “about” interpretation can bound risk.
- Avoiding the precise clinical outcome framing
- Claim 16 is broad: “one or more” endpoints. Harder to avoid if real-world outcomes include stool consistency and diarrhea metrics.
- Targeting a regimen that is marketed or studied for non-overlapping endpoints could reduce mapping, but it does not eliminate risk if the claim is triggered by actual observed improvements.
- Timing/duration modifications to miss dependent claims
- Shorter-than-8-days or outside listed duration windows may reduce exposure under dependent limitations (Claims 5–6, 10–14), but independent claims still focus on method treating stool consistency/watery diarrhea/bowel movement count at ~250 mg/day.
- Demographic limitation avoidance
- Claim 9 includes ancestry restriction. If a competitor could plausibly operate outside that demographic subset, that can reduce alignment for that particular dependent claim. It is not a general carve-out against the independent claims.
What does the claimed regimen imply about the likely underlying clinical study logic?
The claim language is heavily endpoint-anchored (baseline comparisons, daily stool consistency score, abdominal discomfort score, urgency/fecal incontinence days/week, unscheduled visit triggers). That pattern is consistent with:
- diary-based symptom scoring,
- longitudinal responder definitions,
- multi-endpoint efficacy assessments typical for chronic diarrhea studies in HIV populations.
The day-3 and post-day-3 improvement clauses suggest a study that measured early onset kinetics and longitudinal change rather than only endpoint-at-fixed-timepoint efficacy.
Patent landscape considerations for U.S. crofelemer (DGL/antidiarrheal in HIV-associated diarrhea): what else likely coexists around this method patent?
U.S. Patent 8,962,680 is a method-of-treatment patent tied to a dose and clinical endpoints. For a complete infringement and freedom-to-operate map, the operative question is the coexistence of:
- compound/formulation patents on crofelemer,
- earlier method-of-use patents (e.g., HIV-associated diarrhea generally, dose ranges, endpoint types),
- additional method patents covering different dosing frequency, titration, patient subsets, or alternative clinical endpoints,
- and regulatory exclusivity and statutory bars.
Based on the claim set you provided (dose-specific, endpoint-specific, duration and kinetics dependent claims), the surrounding patent estate typically includes multiple layers that can independently block generic entry:
- dose regimen claims (daily amount and BID schedule),
- patient population claims (HIV/HAART-associated),
- endpoint/responder claims (stool consistency and diarrhea burden),
- and potentially formulation delivery method claims if crofelemer is optimized for local gut action.
No additional patent numbers, Orange Book listings, or litigation records can be reliably enumerated from the information provided in your prompt, so an ungrounded enumeration would be inaccurate.
How strong is the claim set as an enforcement asset, based on claim drafting features?
Strength factors
- Specific dose anchors: “about 250 mg/day” and the BID alternative “about 125 mg twice daily.”
- Disease framing is direct and narrow: HIV-positive subject; HIV-associated diarrhea and HAART-associated diarrhea.
- Outcome-based responder language: Claim 16 creates practical evidence paths via trial endpoints and diary-based outcomes.
- Multiple dependent claims: fallback coverage across duration windows, early onset, and symptom subset endpoints.
Potential vulnerability factors
- Dependency complexity: many dependent claims add limitations; if a defendant can show non-fulfillment of particular dependent elements, the patentee may need to pivot to independent claims.
- Demographic limitation: Claim 9 restricts to Caucasian or Hispanic subjects, potentially reducing coverage for that specific dependent claim.
- “About” dosing disputes: infringement hinges on construction of “about” in context, which is fact-intensive.
Key Takeaways
- U.S. Patent 8,962,680 claims crofelemer treatment methods in HIV-positive subjects with ~250 mg/day, including alternative ~125 mg BID dosing, tied to improving stool consistency, reducing watery diarrhea, and decreasing bowel movements.
- The patent’s enforceability lever is endpoint-driven responder definitions (Claim 16) that can be satisfied by multiple diary-based efficacy measures (stool consistency, watery bowel movements, urgency, fecal incontinence, abdominal discomfort, and unscheduled worsening visits).
- Dependent claims add duration (3 days to 6 months; 8 days to 24 weeks; at least 8 days; ~6 months or longer) and response timing (improvement begins day 3; increasing improvement after day 3; response increases after >4 months), creating both additional fallback coverage and potential narrowing defenses.
- The fecal incontinence claim (Claim 22) expands the protected clinical narrative to HIV-associated diarrhea or HAART-associated diarrhea, and coverage is mirrored for 125 mg BID (Claim 27).
FAQs
1) What is the practical “infringement trigger” for 8,962,680?
Administration of crofelemer ~250 mg/day (or ~125 mg BID) to an HIV-positive subject, where clinical outcomes align with the claimed method endpoints or responder definitions.
2) Does 8,962,680 require improvement to occur by day 3?
Only for dependent claims that include the day-3 limitations (e.g., Claim 7). The independent claims you provided are framed around the administration dose and treating specific stool/diarrhea endpoints.
3) Can a different dosing schedule avoid the patent if total daily dose is similar?
The claims you provided explicitly include ~125 mg twice daily as within scope; design-around would need to materially change dosing quantity and/or dosing that avoids the “about” constructs and dependent claim constraints.
4) Does Claim 16 protect more than stool consistency?
Yes. Claim 16’s responder definition includes bowel movements, watery bowel movements, daily abdominal discomfort score, stool consistency measures, urgency, fecal incontinence, and unscheduled worsening visit metrics.
5) Is fecal incontinence use covered only for HIV diarrhea or also HAART diarrhea?
Claim 22 covers fecal incontinence associated with HIV-associated diarrhea or HAART-associated diarrhea, using the same ~250 mg/day crofelemer dose framework.
References
- United States Patent and Trademark Office (USPTO). U.S. Patent No. 8,962,680.
